Association of neutrophil-lymphocyte ratio (NLR) with clinical outcomes in patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with combination of cetuximab and nivolumab (C+N).
Robin Park(Moffitt Cancer Center), Christine H. Chung(Moffitt Cancer Center), Robbert J.C. Slebos(University of Iowa), David Kaldas(University of South Florida), Tyler J. Kristoff(Emory University), James W. Rocco(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Joaquim M. Farinhas(Moffitt Cancer Center), Kedar Kirtane(Moffitt Cancer Center), Nabil F. Saba(Emory University), Ritu Chaudhary(Moffitt Cancer Center), Maria I. Poole(Moffitt Cancer Center), F. Rind(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Sowjanya Thatikonda(Johns Hopkins University), Conor Steuer(Emory University), Priyanka Bhateja(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Marcelo Bonomi, Jiannong Li(Moffitt Cancer Center), Juan C. Hernandez‐Prera(Moffitt Cancer Center)
Cited by 1
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer
|Cell|2017|2.6k
Proteogenomic characterization of human colon and rectal cancer
|Nature|2014|1.6k
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
|New England Journal of Medicine|2008|1.5k